gmac logoconferences
 Key Offerings[conferences][event management][training]
 Conference Specifics[conference overview][conference agenda][conference registration]

June 6, 2002:  Aoyama Diamond Hall, Tokyo, JAPAN

 08:30
REGISTRATION
 09:00

  Introduction from the Chair

 09:15

 Landscape of the Genome Business in Japan in the 21st Century

  • Public and private sector cooperation: Genome business as the project of the millennium
  • Bio-ethics: What will be the code of ethics for human genome and genetics-related business?
  • Common principles within the Japanese Gov't (MEXT,  MHLW and METI), and the Declaration of Helsinki)

Masatoshi Ishizuka, M.D., Ph.D., Director, R & D Promotion Dept.,
The Organization for Pharmaceutical Safety and Research (OPSR)

 10:00

R&D Revolution in the Healthcare Industry

  • The impact of genomics
  • Establishing a strategic value-chain in R&D
  • What is required of top management in the healthcare industry?

Hirotaka Yabuki, Vice President, The Boston Consulting Group K.K.

 10:45
Morning Coffee/Tea and Networking
 11:00

KEYNOTE ADDRESS: 
Kyowa Hakko: Corporate Strategy - Commitment to the Life Science Business -

  • What are the keys to becoming an "R&D-based Global Excellent Company"?
  • Kyowa Hakko's core competence and business portfolio
  • Kyowa Hakko's principles of Environment, Safety and Ethics

Tadashi Hirata, Ph.D., President and Chief Executive Officer,
Kyowa Hakko Kogyo Co., Ltd.

 12:00
LUNCHEON

 13:00


 CASE-STUDY:
Business Strategy in a Post-Genome World
  • From genome to proteome analysis
  • What is the basic technology used for proteome analysis?
  • Why has Cerela changed its business model?

Richard Lussier, Managing Director, Asia & Pacific Region, Celera Genomics

 13:45

 CASE-STUDY:
Bayer's Post-Genome Strategy

  • Bayer's trilateral R&D strategy
  • Bayer's commitment to genome-based pharmaceuticals

Stefan Wohlfeil, Ph.D., Head of Research, Research Center Kyoto,
Bayer Yakuhin, Ltd.

 14:15
Afternoon Coffee/Tea Break and Networking
 14:30

 CASE-STUDY:
AstraZeneca's Global R&D Network

  • Global research and development in the life sciences
  • What are the key points in making global R&D work effectively?
  • What is AstraZeneca's view of the post-life science revolution?

Masuhiro Kato, Ph.D., Vice President, Research & Development,
AstraZeneca K.K.

 15:15

  PANEL DISCUSSION:
Requirements for the Life Science Industry in the 21st Century  

  • Is it possible to revitalize the three key sectors - Business, Government and Academic?
  • Strategic utilization of intellectual property and the cultivation of venture businesses
  • Innovation management of global pharmaceutical companies' R&D divisions
  • Critical factors for the success of the life science business: What is strategic communications?
  • What is the proper role of top management in today's pharmaceutical companies?
Masuhiro Kato, Ph.D.Vice President, R&D,
AstraZeneca K.K.
Takafumi YamamotoPresident, Center for Advanced Science and Technology Incubation Ltd.
Stefan Wohlfeil, Ph.D.Head of Research, Research Center Kyoto,
Bayer Yakuhin, Ltd.
Tsuyoshi Takemura

Managing Director,
Burson-Marsteller, Japan

Hisaji Agata,Managing Director,
JAFCO Co., Ltd.
Martin Reeves Vice President,   
The Boston Consulting Group K.K.

　

 17:15
Closing Comments
　!* Speakers/Agenda are subject to change